Ignite Creation Date:
2024-05-06 @ 7:05 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05881967
Status:
RECRUITING
Last Update Posted:
2023-05-31
First Post:
2023-05-21
Brief Title:
Molecular Mechanism Study of Uterine Sarcoma
Sponsor:
Shixuan Wang
Organization:
Tongji Hospital
Study Overview
Official Title:
Molecular Mechanism Study of Uterine Sarcoma
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this project was to use multi-omics technology to screen the key factors for the occurrence and development of uterine sarcoma
Detailed Description:
Uterine sarcomas are rare mesenchymal neoplasms in the female genital system accounting for about 1 of female reproductive tract malignancies and 37 of uterine malignancies Subtypes of uterine sarcoma are leiomyosarcoma endometrial stromal sarcoma and adenosarcoma Uterine leiomyosarcoma is the most common uterine sarcoma accounting for about 1 to 2 of all uterine malignancies
Uterine sarcomas differ in histologic appearance and clinical behavior The incidence of uterine sarcoma is low and the prognosis is poor Its manifestations mainly include abnormal vaginal bleeding abdominal pain and abdominal mass but none of these symptoms are specific
For uterine sarcoma there are no diagnostic serum markers and imaging features and the diagnosis of uterine sarcoma still mainly depends on postoperative pathological results However with the development of omics technology immunophenotypes and molecular characterization of uterine sarcomas have increasingly been utilized to improve diagnostic classification and prognostication in uterine sarcomas Uterine leiomyosarcoma the most common subtype of uterine sarcoma does not have a single defining molecular abnormality
This project intends to use multi-omics technology to screen the key factors for the occurrence development and malignant transformation of uterine sarcoma especially uterine leiomyosarcoma and to map the interaction network of cell signaling pathways It provides key molecular markers for the early assessment of recurrence and malignant transformation of uterine myoma after conservative treatment and provides a molecular mechanism basis for finding solutions to prevent the progression and malignant transformation
Uterine sarcomas differ in histologic appearance and clinical behavior The incidence of uterine sarcoma is low and the prognosis is poor Its manifestations mainly include abnormal vaginal bleeding abdominal pain and abdominal mass but none of these symptoms are specific
For uterine sarcoma there are no diagnostic serum markers and imaging features and the diagnosis of uterine sarcoma still mainly depends on postoperative pathological results However with the development of omics technology immunophenotypes and molecular characterization of uterine sarcomas have increasingly been utilized to improve diagnostic classification and prognostication in uterine sarcomas Uterine leiomyosarcoma the most common subtype of uterine sarcoma does not have a single defining molecular abnormality
This project intends to use multi-omics technology to screen the key factors for the occurrence development and malignant transformation of uterine sarcoma especially uterine leiomyosarcoma and to map the interaction network of cell signaling pathways It provides key molecular markers for the early assessment of recurrence and malignant transformation of uterine myoma after conservative treatment and provides a molecular mechanism basis for finding solutions to prevent the progression and malignant transformation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None